Polycythemia vera

Common Name(s)

Polycythemia vera

Polycythemia vera (PV) is a condition characterized by an increased number of red blood cells in the bloodstream. Affected people may also have excess white blood cells and platelets. These extra cells cause the blood to be thicker than normal, increasing the risk for blood clots that can block blood flow in arteries and veins. People with PV have an increased risk of deep vein thrombosis which can cause a pulmonary embolism, heart attack, and stroke. Most cases of PV are not inherited and are acquired during a person's lifetime. In rare cases, the risk for PV runs in families and may be inherited in an autosomal dominant manner. The condition has been associated with mutations in the JAK2 and TET2 genes.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Polycythemia vera" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Polycythemia vera" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

http://www.mpdsupport.org

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

http://www.mpnresearchfoundation.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Polycythemia vera" returned 465 free, full-text research articles on human participants. First 3 results:

Spinal cord infarction during physical exertion due to polycythemia vera and aortoiliac occlusive disease: A case report.
 

Author(s): Wei-Pin Lin, Ta-Shen Kuan, Cho-I Lin, Lin-Chieh Hsu, Yu-Ching Lin

Journal: Medicine (Baltimore). 2018 Aug;97(35):e12181.

 

Spinal cord infarction is rarely caused by hypercoagulable states. Polycythemia vera (PV) is a myeloproliferative neoplasm that can contribute to thrombotic events due to increased blood viscosity. We report a case of spinal cord infarction due to extensive aortic thrombosis caused by PV.

Last Updated: 31 Dec 1969

Go To URL
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.
 

Author(s): Martin Griesshammer, Guray Saydam, Francesca Palandri, Giulia Benevolo, Miklos Egyed, Jeannie Callum, Timothy Devos, Serdar Sivgin, Paola Guglielmelli, Caroline Bensasson, Mahmudul Khan, Julian Perez Ronco, Francesco Passamonti

Journal: Ann. Hematol.. 2018 Sep;97(9):1591-1600.

 

RESPONSE-2 is a phase 3 study comparing the efficacy and safety of ruxolitinib with the best available therapy (BAT) in hydroxyurea-resistant/hydroxyurea-intolerant polycythemia vera (PV) patients without palpable splenomegaly. This analysis evaluated the durability of the efficacy ...

Last Updated: 31 Dec 1969

Go To URL
Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report.
 

Author(s): Andreas Hanssønn Habberstad, Hoa Thi Tuyet Tran, Ulla Randen, Signe Spetalen, Ingunn Dybedal, Geir E Tjønnfjord, Anders Erik Astrup Dahm

Journal:

 

Polycythemia vera is a myeloproliferative disease that sometimes evolves to myelofibrosis, causing splenomegaly and neutropenia. In this case report, we describe a patient with polycythemia vera and unexplained neutropenia who later turned out to also have hairy cell leukemia.

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Polycythemia vera" returned 37 free, full-text review articles on human participants. First 3 results:

Polycythemia vera treatment algorithm 2018.
 

Author(s): Ayalew Tefferi, Alessandro M Vannucchi, Tiziano Barbui

Journal:

 

Recently reported mature survival data have confirmed the favorable prognosis in polycythemia vera (PV), with an estimated median survival of 24 years, in patients younger than age 60 years old. Currently available drugs for PV have not been shown to prolong survival or alter the ...

Last Updated: 31 Dec 1969

Go To URL
No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials.
 

Author(s): Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Arianna Masciulli, Alessandro Rambaldi, Alessandro M Vannucchi

Journal: Haematologica. 2017 06;102(6):e219-e221.

 

Last Updated: 31 Dec 1969

Go To URL
Polycythemia Vera Management and Challenges in the Community Health Setting.
 

Author(s): Aaron T Gerds, Kim-Hien Dao

Journal: Oncology. 2017 ;92(4):179-189.

 

Patients with polycythemia vera (PV) experience shortened survival, increased risk of thromboembolic and hemorrhagic events, and burdensome symptoms. For all patients with PV, treatment with aspirin and hematocrit control with phlebotomy are recommended. In addition, patients with ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
 

Status: Recruiting

Condition Summary: Polycythemia Vera

 

Last Updated: 26 Sep 2018

Go to URL

Last Updated: 7 Jul 2018

Go to URL